{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:09:13Z","timestamp":1790636953903,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Incyte Corporation, Wilmington, DE, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1007\/s13555-024-01219-8","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T08:02:51Z","timestamp":1720771371000},"page":"2139-2151","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ruxolitinib Cream in Adolescents\/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase\u00a03 Studies"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03745638","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-0252","authenticated-orcid":false,"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0831-2151","authenticated-orcid":false,"given":"Leon","family":"Kircik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2633-985X","authenticated-orcid":false,"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5634-883X","authenticated-orcid":false,"given":"Howard","family":"Kallender","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4413-8429","authenticated-orcid":false,"given":"Daniel","family":"Sturm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyue","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0474","authenticated-orcid":false,"given":"Lawrence F.","family":"Eichenfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"issue":"10247","key":"1219_CR1","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/S0140-6736(20)31286-1","volume":"396","author":"SM Langan","year":"2020","unstructured":"Langan SM, Irvine AD, Weidinger S. Atopic dermatitis. Lancet. 2020;396(10247):345\u201360.","journal-title":"Lancet"},{"issue":"1","key":"1219_CR2","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","volume":"71","author":"LF Eichenfield","year":"2014","unstructured":"Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116\u201332.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"1219_CR3","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.jaad.2017.06.042","volume":"77","author":"EL Simpson","year":"2017","unstructured":"Simpson EL, Bruin-Weller M, Flohr C, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. J Am Acad Dermatol. 2017;77(4):623\u201333.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"1219_CR4","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/jdv.18345","volume":"36","author":"A Wollenberg","year":"2022","unstructured":"Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I - systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409\u201331.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5","key":"1219_CR5","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1111\/jdv.14891","volume":"32","author":"A Wollenberg","year":"2018","unstructured":"Wollenberg A, Barbarot S, Bieber T, et al. Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. J Eur Acad Dermatol Venereol. 2018;32(5):657\u201382.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1219_CR6","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jaad.2022.08.068","volume":"89","author":"R Sidbury","year":"2023","unstructured":"Sidbury R, Alikhan A, Bercovitch L, et al. Executive summary: American Academy of Dermatology guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89(1):128\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"1219_CR7","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1016\/j.jaci.2019.11.025","volume":"145","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Thaci D, Pangan AL, et al. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. J Allergy Clin Immunol. 2020;145(3):877\u201384.","journal-title":"J Allergy Clin Immunol"},{"issue":"24","key":"1219_CR8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","volume":"375","author":"EL Simpson","year":"2016","unstructured":"Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase\u00a03 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375(24):2335\u201348.","journal-title":"N Engl J Med"},{"issue":"3","key":"1219_CR9","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","volume":"184","author":"A Wollenberg","year":"2021","unstructured":"Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase\u00a0III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437\u201349.","journal-title":"Br J Dermatol"},{"issue":"4","key":"1219_CR10","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1001\/jamadermatol.2020.0079","volume":"156","author":"E Guttman-Yassky","year":"2020","unstructured":"Guttman-Yassky E, Blauvelt A, Eichenfield LF, et al. Efficacy and safety of lebrikizumab, a high-affinity interleukin 13 inhibitor, in adults with moderate to severe atopic dermatitis: a phase\u00a02b randomized clinical trial. JAMA Dermatol. 2020;156(4):411\u201320.","journal-title":"JAMA Dermatol"},{"issue":"12","key":"1219_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312.","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"1219_CR12","doi-asserted-by":"publisher","first-page":"10S","DOI":"10.1177\/1203475418803628","volume":"22","author":"MJ Gooderham","year":"2018","unstructured":"Gooderham MJ, Bissonnette R, Grewal P, Lansang P, Papp KA, Hong CH. Approach to the assessment and management of adult patients with atopic dermatitis: a consensus document. Section II: tools for assessing the severity of atopic dermatitis. J Cutaneous Med Surg. 2018;22(suppl 1):10S\u20136S.","journal-title":"J Cutaneous Med Surg"},{"issue":"4","key":"1219_CR13","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/bjd.16078","volume":"178","author":"PP Vakharia","year":"2018","unstructured":"Vakharia PP, Chopra R, Sacotte R, et al. Severity strata for five patient-reported outcomes in adults with atopic dermatitis. Br J Dermatol. 2018;178(4):925\u201330.","journal-title":"Br J Dermatol"},{"issue":"15","key":"1219_CR14","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","volume":"115","author":"A Quintas-Cardama","year":"2010","unstructured":"Quintas-Cardama A, Vaddi K, Liu P, et al. Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood. 2010;115(15):3109\u201317.","journal-title":"Blood"},{"issue":"4","key":"1219_CR15","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.jaad.2021.04.085","volume":"85","author":"K Papp","year":"2021","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: results from two phase\u00a03, randomized, double-blind studies. J Am Acad Dermatol. 2021;85(4):863\u201372.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"1219_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.jaad.2022.09.060","volume":"88","author":"K Papp","year":"2023","unstructured":"Papp K, Szepietowski JC, Kircik L, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase\u00a03 studies. J Am Acad Dermatol. 2023;88(5):1008\u201316.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"1219_CR17","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373.","journal-title":"JAMA Dermatol"},{"key":"1219_CR18","doi-asserted-by":"publisher","first-page":"AB148","DOI":"10.1016\/j.jaad.2021.06.605","volume":"85","author":"A Blauvelt","year":"2021","unstructured":"Blauvelt A, Eichenfield LF, Kuligowski ME, et al. Efficacy of ruxolitinib cream among patients with atopic dermatitis based on previous medication history: pooled results from two phase\u00a03 studies. Am Acad Dermatol Virt Meeting Exp. 2021;85:AB148.","journal-title":"Am Acad Dermatol Virt Meeting Exp"},{"issue":"3","key":"1219_CR19","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-022-00690-3","volume":"23","author":"R Bissonnette","year":"2022","unstructured":"Bissonnette R, Call RS, Raoof T, et al. A maximum-use trial of ruxolitinib cream in adolescents and adults with atopic dermatitis. Am J Clin Dermatol. 2022;23(3):355\u201364.","journal-title":"Am J Clin Dermatol"},{"issue":"4","key":"1219_CR20","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1159\/000446068","volume":"232","author":"SM Muller","year":"2016","unstructured":"Muller SM, Tomaschett D, Euler S, Vogt DR, Herzog L, Itin P. Topical corticosteroid concerns in dermatological outpatients: a cross-sectional and interventional study. Dermatology. 2016;232(4):444\u201352.","journal-title":"Dermatology"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01219-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T14:28:49Z","timestamp":1724077729000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01219-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":20,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["1219"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01219-8","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"30 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric L. Simpson is an investigator for AbbVie, Eli Lilly, Galderma, Kyowa Hakko Kirin, LEO Pharma, Merck, Pfizer, and Regeneron; and is a consultant with honorarium for AbbVie, Eli Lilly, Forte Bio, Galderma, Incyte, LEO Pharma, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and Valeant. Leon Kircik has served as an investigator, consultant, or speaker for AbbVie, Amgen, Anaptys, Arcutis, Dermavant, Eli Lilly, Glenmark, Incyte, Kamedis, LEO Pharma, L\u2019Oreal, Menlo Therapeutics, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and Taro. Andrew Blauvelt is a member and owner of Blauvelt Consulting and has served as a speaker (received honoraria) for AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron, and Sanofi, served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, Leo, Merck, Novartis, Pfizer, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Vibliome, and Xencor, and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma. Howard Kallender and Daniel Sturm are employees and shareholders of Incyte. Mingyue Wang (currently at Boehringer Ingelheim) was an employee of Incyte at the time of the study and is a shareholder of Incyte. Lawrence F. Eichenfield has served as a consultant, speaker, advisory board member, or investigator for AbbVie, Amgen, Arcutis, Aslan, Bristol Myers Squibb, Castle Biosciences, Dermavant, Eli Lilly, Forte, Galderma, Incyte, Janssen, Johnson & Johnson, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi-Genzyme, Target RWE, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"These studies were conducted in accordance with Good Clinical Practice guidelines and the provisions of the Declaration of Helsinki. All patients provided written informed consent before enrollment. The protocols were approved by the relevant institutional review board or ethics committee at each study center (Supplementary Materials Tables\u00a0 and ).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}